Gilead Sciences Inc (NASDAQ:GILD)

89.04
Delayed Data
As of Dec 02
 +1.14 / +1.30%
Today’s Change
57.17
Today|||52-Week Range
89.07
+22.63%
Year-to-Date
Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?
Dec 02 / Zacks.com - Paid Partner Content
AstraZeneca (AZN) Boosts Cell Therapies With Neogene Deal
Nov 30 / Zacks.com - Paid Partner Content
Roivant (ROIV), Pfizer Form Vant for Inflammatory Disease Drug
Dec 02 / Zacks.com - Paid Partner Content
Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion
Nov 30 / Zacks.com - Paid Partner Content
Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?
Dec 01 / Zacks.com - Paid Partner Content
The 3 Best Dividend Stocks to Purchase Right Now
Nov 30 / StockNews.com - Paid Partner Content
The Top Healthcare Stocks to Buy With $100
Dec 01 / MotleyFool.com - Paid Partner Content
These 3 Stocks Are Rallying While the Rest of the Market Plunges
Nov 30 / MotleyFool.com - Paid Partner Content
2 Reasons This Stock Could Outperform in 2023
Nov 30 / MotleyFool.com - Paid Partner Content
3 Biotech Stocks to Buy Before December and 1 to Sell
Nov 30 / StockNews.com - Paid Partner Content

Today’s Trading

Previous close87.90
Today’s open86.70
Day’s range86.53 - 89.07
Volume390,843
Average volume (3 months)7,816,840
Market cap$111.7B
Data as of 4:00pm ET, 12/02/2022

Growth & Valuation

Earnings growth (last year)+4,962.51%
Earnings growth (this year)-2.68%
Earnings growth (next 5 years)+0.30%
Revenue growth (last year)+11.08%
P/E ratio33.7
Price/Sales3.35
Price/Book5.30

Competitors

----
AMGNAmgen-0.44-0.15%
MRNAModerna Inc+0.87+0.48%
BIIBBiogen-3.03-1.00%
Data as of 4:00pm ET, 12/02/2022

Financials

Next reporting dateFebruary 7, 2023
EPS forecast (this quarter)$1.50
Annual revenue (last year)$27.4B
Annual profit (last year)$6.2B
Net profit margin22.74%

Profile

Sector
Health Technology
Industry
Biotechnology
No executives to display
Corporate headquarters
Foster City, California

Forecasts